Nautilus Biotechnology, Inc.

Nautilus Biotechnology, Inc.

NAUT·NASDAQ

$2.58

-3.7%
HealthcareBiotechnology

Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. It develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis. The company was founded in 2016 and is headquartered in Seattle, Washington.

At a Glance

Live Snapshot
Market Cap$327.86M
EPS-0.4700
P/E Ratio-5.49
Earnings Date08/04/2026

naut

Net Interest Income

Last Annual Value

7.87M

3-Year CAGR

%

5-Year CAGR

%

10-Year CAGR

%

Nautilus Biotechnology, Inc.

Nautilus Biotechnology, Inc. Competitors Analysis of Net Interest Income

NAUT · NASDAQ
CompanyNet Interest Income
CAGR 3Y
CAGR 5Y
CAGR 10Y
7.87M
-14.4%88.7%N/A 
2.68M
-27.6%90.1%N/A
ZURA logo
Zura Bio Limited
NASDAQ:ZURA
6.34M
42.6%206.4%N/A
HUMA logo
Humacyte, Inc.
NASDAQ:HUMA
-8.66M
N/AN/AN/A
10.10M
-15.3%N/AN/A
0.00
N/AN/AN/A
3.04M
-5.5%78.0%N/A
AGEN logo
Agenus Inc.
NASDAQ:AGEN
-55.27M
N/AN/AN/A
-13.00K
N/AN/AN/A
3.38M
42.6%N/AN/A
-489.05K
N/AN/AN/A
Nautilus Biotechnology, Inc.

Nautilus Biotechnology, Inc. Fair Value Envelope

NAUT · NASDAQ

Our analysis suggests that NAUT has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $2.58, this represents a potential HIDDEN relative to our calculated worth for Nautilus Biotechnology, Inc..

Intrinsic Value
Current Price: $2.58